Significant regulatory developments are shaping the biotech sector. The FDA has initiated daily publishing of drug adverse event reports to improve transparency and post-market surveillance. Meanwhile, the Supreme Court upheld the Trump administration's defunding of $783 million in NIH diversity-related research grants, impacting federal science funding. Multiple FDA new molecular entity approvals continue to contribute to robust industry momentum.